CClinicalTrials.gg
Sign In
Status unknownNCT02270593Updated Oct 21, 2014

ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta).

An observational study in Placenta Previa, sponsored by Zekai Tahir Burak Women's Health Research and Education Hospital. Status unknown at 1 site in Turkey. Open to female participants aged 25 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-21.

Sponsored by Zekai Tahir Burak Women's Health Research and Education Hospital · Observational

The sponsor has not verified this record recently (last verified Oct 2014), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
25 Years to 40 Years
Sex
Female
01

Study summary

Placenta previa totalis (accreta, increta, percreta); ADAMTS and proteoglycans and the oxidant / antioxidant enzyme levels.

Read the detailed description

Placenta previa totalis (accreta, increta, percreta) of pregnant women in the maternal serum, fetal membranes (placenta) and hysterectomy of women with myometrial strips measured the ADAMTS and proteoglycans expression levels, and the oxidant / antioxidant enzyme levels.

02

Conditions studied

  • Placenta Previa

Browse trials for

03

In context

Placenta Previa

93 studies on the registry are indexed under Placenta Previa; 20 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 37 observational studies indexed under Placenta Previa.

Browse Placenta Previa studies →

Lead sponsor

Zekai Tahir Burak Women's Health Research and Education Hospital is the lead sponsor of 62 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

tertiary health institutions

Inclusion criteria

  • pregnant women diagnosed with placenta previa by obstetric ultrasound and doppler

Exclusion criteria

Exclusion Criteria:

  • Pregnant women with comorbid diseases other than previa totalis .
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
None retained

Groups and cohorts

  • Placenta previa

    first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).

06

What researchers measure

Primary outcomes

  1. ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of maternal serum in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta)

    Time frame: Up to 6 months

Secondary outcomes

  1. ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of myometrial samples in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta)

    Time frame: Up to 6 months

  2. ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Fetal Membranes in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta)

    Time frame: Up to 6 months

  3. placenta previa totalis in the development, progression and in exacerbating; ADAMTS and proteoglycans, to determine the relationship of changes in expression.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Zekai Tahir Burak Women's Health Education and Research Hospital
    Ankara, Turkey
    • SİBEL ÖZLER, MD · Contact · 0(312)30650000
    • AHMET NURİ DANIŞMAN, MD · Principal investigator
    • ALİ TURHAN ÇAĞLAR, MD · Sub investigator
    • SİBEL ÖZLER, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02270593
Lead sponsor
Zekai Tahir Burak Women's Health Research and Education Hospital
Responsible party
sibel özler (ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta), Zekai Tahir Burak Women's Health Research and Education Hospital) — Principal investigator
First posted
Oct 21, 2014
Start date
Aug 2013
Primary completion
Dec 2014 (estimated)
Completion
Oct 2015 (estimated)
Last update
Oct 21, 2014

Study contacts

sibel özler, md
Contact
sibelozler@gmail.com
05457970257
ahmet nuri danısman, md
study director · zekai tahir burak women's health education and research hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Placenta Previa→

Other studies from this sponsor

Zekai Tahir Burak Women's Health Research and Education Hospital

Start the discussion